Literature DB >> 28069571

APC/C Dysfunction Limits Excessive Cancer Chromosomal Instability.

James O Patterson1, Sally Dewhurst1, Laurent Sansregret1, Carlos López-García1, André Koch2, Nicholas McGranahan1,3, William Chong Hang Chao1, David J Barry1, Andrew Rowan1, Rachael Instrell1, Stuart Horswell1, Michael Way1, Michael Howell1, Martin R Singleton1, René H Medema2, Paul Nurse1, Mark Petronczki1,4, Charles Swanton1,3.   

Abstract

Intercellular heterogeneity, exacerbated by chromosomal instability (CIN), fosters tumor heterogeneity and drug resistance. However, extreme CIN correlates with improved cancer outcome, suggesting that karyotypic diversity required to adapt to selection pressures might be balanced in tumors against the risk of excessive instability. Here, we used a functional genomics screen, genome editing, and pharmacologic approaches to identify CIN-survival factors in diploid cells. We find partial anaphase-promoting complex/cyclosome (APC/C) dysfunction lengthens mitosis, suppresses pharmacologically induced chromosome segregation errors, and reduces naturally occurring lagging chromosomes in cancer cell lines or following tetraploidization. APC/C impairment caused adaptation to MPS1 inhibitors, revealing a likely resistance mechanism to therapies targeting the spindle assembly checkpoint. Finally, CRISPR-mediated introduction of cancer somatic mutations in the APC/C subunit cancer driver gene CDC27 reduces chromosome segregation errors, whereas reversal of an APC/C subunit nonsense mutation increases CIN. Subtle variations in mitotic duration, determined by APC/C activity, influence the extent of CIN, allowing cancer cells to dynamically optimize fitness during tumor evolution. SIGNIFICANCE: We report a mechanism whereby cancers balance the evolutionary advantages associated with CIN against the fitness costs caused by excessive genome instability, providing insight into the consequence of CDC27 APC/C subunit driver mutations in cancer. Lengthening of mitosis through APC/C modulation may be a common mechanism of resistance to cancer therapeutics that increase chromosome segregation errors. Cancer Discov; 7(2); 218-33. ©2017 AACR.See related commentary by Burkard and Weaver, p. 134This article is highlighted in the In This Issue feature, p. 115. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28069571      PMCID: PMC5300100          DOI: 10.1158/2159-8290.CD-16-0645

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  78 in total

1.  Cytokinesis failure triggers hippo tumor suppressor pathway activation.

Authors:  Neil J Ganem; Hauke Cornils; Shang-Yi Chiu; Kevin P O'Rourke; Jonathan Arnaud; Dean Yimlamai; Manuel Théry; Fernando D Camargo; David Pellman
Journal:  Cell       Date:  2014-08-14       Impact factor: 41.582

Review 2.  The causes and consequences of polyploidy in normal development and cancer.

Authors:  Teresa Davoli; Titia de Lange
Journal:  Annu Rev Cell Dev Biol       Date:  2011-07-21       Impact factor: 13.827

3.  Telomere dysfunction and evolution of intestinal carcinoma in mice and humans.

Authors:  K L Rudolph; M Millard; M W Bosenberg; R A DePinho
Journal:  Nat Genet       Date:  2001-06       Impact factor: 38.330

4.  Cut homeobox 1 causes chromosomal instability by promoting bipolar division after cytokinesis failure.

Authors:  Laurent Sansregret; Charles Vadnais; Julie Livingstone; Nicholas Kwiatkowski; Arif Awan; Chantal Cadieux; Lam Leduy; Michael T Hallett; Alain Nepveu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-18       Impact factor: 11.205

5.  Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage.

Authors:  Xing Zeng; Frederic Sigoillot; Shantanu Gaur; Sungwoon Choi; Kathleen L Pfaff; Dong-Chan Oh; Nathaniel Hathaway; Nevena Dimova; Gregory D Cuny; Randall W King
Journal:  Cancer Cell       Date:  2010-10-19       Impact factor: 31.743

6.  Chromosome missegregation rate predicts whether aneuploidy will promote or suppress tumors.

Authors:  Alain D Silk; Lauren M Zasadil; Andrew J Holland; Benjamin Vitre; Don W Cleveland; Beth A Weaver
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-16       Impact factor: 11.205

Review 7.  The spindle-assembly checkpoint in space and time.

Authors:  Andrea Musacchio; Edward D Salmon
Journal:  Nat Rev Mol Cell Biol       Date:  2007-04-11       Impact factor: 94.444

8.  Cell populations can use aneuploidy to survive telomerase insufficiency.

Authors:  Caroline Millet; Darya Ausiannikava; Thierry Le Bihan; Sander Granneman; Svetlana Makovets
Journal:  Nat Commun       Date:  2015-10-22       Impact factor: 14.919

9.  Atomic structure of the APC/C and its mechanism of protein ubiquitination.

Authors:  Leifu Chang; Ziguo Zhang; Jing Yang; Stephen H McLaughlin; David Barford
Journal:  Nature       Date:  2015-06-15       Impact factor: 49.962

10.  Acquisition of aneuploidy provides increased fitness during the evolution of antifungal drug resistance.

Authors:  Anna M Selmecki; Keely Dulmage; Leah E Cowen; James B Anderson; Judith Berman
Journal:  PLoS Genet       Date:  2009-10-30       Impact factor: 5.917

View more
  40 in total

1.  Chromosome Mis-segregation Generates Cell-Cycle-Arrested Cells with Complex Karyotypes that Are Eliminated by the Immune System.

Authors:  Stefano Santaguida; Amelia Richardson; Divya Ramalingam Iyer; Ons M'Saad; Lauren Zasadil; Kristin A Knouse; Yao Liang Wong; Nicholas Rhind; Arshad Desai; Angelika Amon
Journal:  Dev Cell       Date:  2017-06-19       Impact factor: 12.270

Review 2.  APC/C ubiquitin ligase: Functions and mechanisms in tumorigenesis.

Authors:  Morgan S Schrock; Benjamin R Stromberg; Luke Scarberry; Matthew K Summers
Journal:  Semin Cancer Biol       Date:  2020-03-09       Impact factor: 15.707

3.  Overexpression of hsa-miR-186 induces chromosomal instability in arsenic-exposed human keratinocytes.

Authors:  Jiguo Wu; Ana P Ferragut Cardoso; Vanessa A R States; Laila Al-Eryani; Mark Doll; Sandra S Wise; Shesh N Rai; J Christopher States
Journal:  Toxicol Appl Pharmacol       Date:  2019-06-06       Impact factor: 4.219

4.  Interrogating cell division errors using random and chromosome-specific missegregation approaches.

Authors:  Peter Ly; Don W Cleveland
Journal:  Cell Cycle       Date:  2017-06-26       Impact factor: 4.534

Review 5.  Determinants and clinical implications of chromosomal instability in cancer.

Authors:  Laurent Sansregret; Bart Vanhaesebroeck; Charles Swanton
Journal:  Nat Rev Clin Oncol       Date:  2018-01-03       Impact factor: 66.675

6.  Hyperphosphorylation of CDH1 in Glioblastoma Cancer Stem Cells Attenuates APC/CCDH1 Activity and Pharmacologic Inhibition of APC/CCDH1/CDC20 Compromises Viability.

Authors:  Kuntal De; Treg M Grubb; Abigail A Zalenski; Kayla E Pfaff; Debjani Pal; Shubhra Majumder; Matthew K Summers; Monica Venere
Journal:  Mol Cancer Res       Date:  2019-04-29       Impact factor: 5.852

7.  Cezanne/OTUD7B is a cell cycle-regulated deubiquitinase that antagonizes the degradation of APC/C substrates.

Authors:  Thomas Bonacci; Aussie Suzuki; Gavin D Grant; Natalie Stanley; Jeanette G Cook; Nicholas G Brown; Michael J Emanuele
Journal:  EMBO J       Date:  2018-07-04       Impact factor: 11.598

8.  Tuning Chromosomal Instability to Optimize Tumor Fitness.

Authors:  Mark E Burkard; Beth A Weaver
Journal:  Cancer Discov       Date:  2017-02       Impact factor: 39.397

Review 9.  Targeting the cell cycle in breast cancer: towards the next phase.

Authors:  K L Thu; I Soria-Bretones; T W Mak; D W Cescon
Journal:  Cell Cycle       Date:  2018-09-11       Impact factor: 4.534

10.  Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer.

Authors:  K L Thu; J Silvester; M J Elliott; W Ba-Alawi; M H Duncan; A C Elia; A S Mer; P Smirnov; Z Safikhani; B Haibe-Kains; T W Mak; D W Cescon
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.